“…A comparison of SNP array data revealed that CRYAB is gained or amplified in many cancers such as B-Cell neoplasms, non-small cell lung cancer, glioblastoma, melanoma, colorectal, bladder, pancreatic, breast, endometrial, renal, thyroid cancer, and sarcoma (Fig S1a and negative correlation with hormone expression (Fig S2a , 2b and 2c). Consistent with this, CRYAB overexpression predominantly occurs in triple-negative breast cancer that lack expression of hormone receptors 7 . Notably, autophagy, angiogenesis and, hypoxia have a significant-positive correlation to CRYAB expression across several cancer types such as adenocarcinomas of colon, lung, prostate, and stomach (Fig S2c ,).…”